OncoSec Medical to Present at DNA Vaccines Conference 2011

  //health-fitness.news-articles.net/content/2011/ .. -to-present-at-dna-vaccines-conference-2011.html
  Published in Health and Fitness on Monday, July 11th 2011 at 3:20 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

OncoSec Medical to Present at DNA Vaccines Conference 2011 -- SAN DIEGO, July 11, 2011 /PRNewswire/ --

[ ]

[ Download image ]

SAN DIEGO, July 11, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that the company will present at the Annual DNA Vaccines Conference, hosted by the International Society of DNA Vaccines, July 12-14 at the Loews Coronado Bay hotel in San Diego, California. This year's conference is themed, "Building on Clinical Progress and Exploring New Targets."

(Logo: [ http://photos.prnewswire.com/prnh/20110314/MM64943LOGO ])

Richard Heller, Ph.D., director of the Frank Reidy Research Center for Bioelectrics at Old Dominion University and eminent leader in the field of electroporation, as well as Adil Daud, M.D., co-director of the Melanoma Center at the University of California, San Francisco, and principal investigator for OncoSec's upcoming Phase II melanoma clinical trial will be presenting at the 2011 DNA Vaccines Conference on behalf of OncoSec.

Richard Heller, PhD - Director and Professor, Frank Reidy Research Center for Bioelectrics
"Immunotherapy for Cancer Facilitated by Electro Gene Transfer"
July 14, 2011
2:00 - 2:30 PM

Adil Daud, MD - Clinical Professor of Medicine, University of California, San Francisco Electroporative"Gene Therapy with IL-12 Plasmid in Metastatic Melanoma"
July 14, 2011
2:30 - 3:00pm

About OncoSec Medical Inc.

OncoSec Medical (OTCBB: ONCS) develops novel ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials. More information is available at [ www.oncosec.com ].

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SOURCE OncoSec Medical Incorporated

RELATED LINKS
[ http://www.oncosec.com ]